Do Orally Administered Immunoglobulin-Based Agents Represent the Future of IBD Therapeutics?
Crossref DOI link: https://doi.org/10.1007/S10620-015-3802-X
Published: 2015-11
Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY
Shapiro, Jason M.
Kerur, Basavaraj
Text and Data Mining valid from 2015-07-17